DTIL
Precision Biosciences Inc.
A clinical-stage gene editing company whose ARCUS platform, built on a naturally occurring enzyme first found in green algae, develops therapies for chronic hepatitis B and Duchenne muscular dystrophy. Three Duke University postdocs founded the company in 2006 after their lab discovery placed second in a university start-up challenge, and the earliest ARCUS work actually edited crops like corn and soybean before turning to human medicines.
CUSIP: 74019P207HealthcareUS1 holder
Feb 14, 2024 — Reclassified from Precision Biosciences Inc. (1:1)
Total Value
$2.15M
Total Shares
274.1K
Net Share Change
+95.0K
Activity
1 buying
Investor
Value
Shares
Weight
Change
